Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3474 in advanced solid tumors
NCT04144855Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3474 in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
TQB3474
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04144855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144855.